Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCT01192880
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Bitopertin, Antipsychotics
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

NCT03496623
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled treprostinil solution, Placebo solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Timing of Insulin Before Meals Everyday

NCT00789945
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control, Study Arm B
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 29, 2026, 4:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575
View directory record Official record
Conditions
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions
Dapansutrile, Placebo Tablet
Drug · Other
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT00682981
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Obatoclax, Carboplatin/etoposide
Drug
Lead sponsor
Gemin X
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
View directory record Official record
Conditions
Light Chain (AL) Amyloidosis
Interventions
Birtamimab, Placebo, Standard of Care Chemotherapy
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

NCT05053139
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients

NCT04106609
View directory record Official record
Conditions
Breast Cancer
Interventions
Supervised, individualized exercise oncology program, Current standard of care
Other
Lead sponsor
Karen Wonders
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

NCT00587444
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Heparin, HH or high heparin, heparin concentration HC
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Phase 4 Interventional

Effect of Continuing Versus Holding Metformin During Hospitalizations.

NCT06296836
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 110 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Not applicable Interventional

Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome

NCT04428567
View directory record Official record
Conditions
Fragile X Associated Tremor-ataxia Syndrome
Interventions
Dual-Task Treadmill exercise + Cognitive Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

NCT03393975
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755, Standard of care
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
0 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

NCT00475800
View directory record Official record
Conditions
Osteoarthritis
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Timeline
Started 2004
U.S. locations
5
States / cities
Tucson, Arizona • Brooklyn Park, Minnesota • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 29, 2026, 4:42 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Calcium Carbonate to Augment Labor Contractions

NCT06580782
View directory record Official record
Conditions
Labor Dystocia, Labor Induction, Labor Augmentation
Interventions
Calcium Carbonate 500 MG, Standard Dose Synthetic Pitocin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Regimen for the Treatment of Cachexia in Subjects With NSCLC

NCT00527319
View directory record Official record
Conditions
Cachexia
Interventions
VT-122 low dose, VT-122 high dose
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 29, 2026, 4:42 PM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Remote Ischemic Conditioning in HSCT

NCT04808167
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantations
Interventions
autoRIC®
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

NCT03938545
View directory record Official record
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 29, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019
View directory record Official record
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Watertown, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 29, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Calcium Carbonate on Labor Induction

NCT06352775
View directory record Official record
Conditions
Pregnancy, Uterine Contraction
Interventions
Calcium Carbonate
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 4:42 PM EDT